United States Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	May 2008
Publisher	Business Monitor
Product Type	Report
Pages	110
ISBN Number	1748-3778
Product Code	BMI01189

Price

£425.00
approximately: $794 | €539

PDF immediate delivery

Order above formats by FAX

Summary

Despite concerns over the economy, the US drug market should continue its solid growth in the coming years with BMI expecting a compound annual growth rate (CAGR) of 3.99% for 2007-2012. By the end of the forecast period total drug expenditure should reach US$364.7bn.

The key driver of growth is swelling health expenditure, which in the next five years should breach the US$3trn mark. According to data from the OECD, in 1980 the US spent 8.8% of GDP on health. In 2012, BMI estimates that this will have risen to 17.9%, by far the highest level in the world. The event that will have the most impact on health expenditure will be the Presidential election in 2008. The two leading Democratic candidates - Barack Obama and Hillary Clinton - have both pledged to implement universal health systems if elected. However, it is difficult to know whether this would have an inflationary or deflationary impact. Less emphasis on the private sector might stop health insurance premiums spiralling upwards, but bringing more than 40mn uninsured citizens under coverage will also require increased spending. Meanwhile, underlying trends such as the rapidly ageing population and increasing numbers of retirees will continue unabated.

One problem that drugmakers are complaining about is raised approval standards at the US FDA, meaning that fewer product candidates are making the grade. Jean-Paul Garnier, CEO of GlaxoSmithKline (GSK), claims that his company is preparing 25 launches over the next few years, but a number are being delayed, which would not have been delayed two years ago. This has caused BMI to slightly downgrade the US's Business Environment Ranking, although the country is still comfortably the leader in the Americas region and is still at the top of the global rankings ahead of Switzerland.

Tougher operating conditions have not deterred FDI. Over the past quarter a number of US assets have been snapped up with OTC firm Adams Respiratory Therapeutics being bought by UK-based Reckitt Benckiser. Japanese drugmaker Astellas has also acquired US-based biotech firm Agensys in a deal worth US$537mn, as it looks to expand its portfolio of monoclonal antibody (MAb) therapies. The falling dollar, meanwhile, has played into the hands of domestic drugmakers, such as Schering-Plough, with a strong presence overseas.

Content

Executive Summary
US Pharmaceuticals And Healthcare Industry SWOT
United States Political SWOT
United States Economic SWOT
US Pharmaceutical Business Environment Ratings
Limits To Potential Returns
United States - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Industry Developments
Healthcare Sector
Universal Healthcare
Part D
Democrats Controlling Congress
Biotechnology Sector
Statins
Advertising Sector
Product Approvals
Merck Settles Over Vioxx
Mergers And Acquisitions
Marketing Sector
Research And Development Sector
Generics Sector
Wal-Mart Enters The Fray
Authorised Generics
Biogenerics
Canadian Imports
Pharmacy Sector
Manufacturing Sector
Vaccine-preventable Diseases
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Patented Market Forecast
OTC Market Forecast
Generics Market Forecast
Export/Import Forecasts
Other Healthcare Data
Competitive Landscape
Overview
Market Data
Company Profiles
Pfizer
GlaxoSmithKline (GSK)
Novartis
Merck & Co
Eli Lilly
Bristol-Myers Squibb (BMS)
Amgen
Genentech
BMI Forecast Modellin106
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Sources ...................................................................................
List of Tables
- Table: Americas Pharmaceutical Business Environment Rankings
- Table: US Health Insurance Key States, 2005
- Table: Biotechnology Medicines Under Development, 2006
- Table: Top 10 Biotech IPOs, 2006
- Table: US Pharmaceuticals And Healthcare Sector - Historical Data And Forecasts
- Table: United States - Macroeconomic Forecasts
- Table: Patented Market Indicators
- Table: OTC Market Indicators (US$mn unless otherwise stated)
- Table: Generics And Patented Market Indicators
- Table: US Pharmaceuticals And Healthcare Sector (US$mn)
- Table: US Pharmaceuticals And Healthcare Sector
- Table: US Pharmaceuticals And Healthcare Sector
- Table: Leading 10 Therapeutic Classes By US Sales, 2006
- Table: Leading 10 Products By US Sales, 2006
- Table: 10 Leading Corporations By US Sales, 2006
- Table: 10 Leading Corporations By Total US Dispensed Prescriptions, 2006
- Table: Channel Distribution By US Dispensed Prescription, 2006
- Table: Channel Distribution By US Sales, 2006
- Table: Leading 10 Products By Total US Dispensed Prescriptions, 2006
- Table: HMG-COA Reductase Inhibitors (statins) - Total US Sales (US$'000)
- Table: Proton Pump Inhibitors - Total US Sales (US$'000)
- Table: Antidepressants (includes SSRI, SNRI and newer generation) - Total US Sales (US$'000)
- Table: Antiarthitics, COX-2 Inhibitors - Total US Sales (US$'000)
- Table: Sexual Function Disorder - Total US Sales (US$'000)
- Table: Pharmaceutical Business Environment Indicators

About this Product

Delivery Details

PDF:Immediate delivery

Ask a question about this product?

Need help finding the right product?

Product features / use

Scope	Expert Insight/Opinion
Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted